Journal of Shanghai Jiao Tong University (Medical Science) >

2025 , Vol. 45 >Issue 11: 1443 - 1457

DOI: https://doi.org/10.3969/j.issn.1674-8115.2025.11.004

Basic research

LINC01123 promotes proliferation and glycolysis of gastric cancer via binding to ENO1

  • ZHANG Shuqiong ,
  • KE Xing ,
  • ZHAO Xinghe ,
  • CHEN Xiaocui ,
  • ZHENG Haodong ,
  • CHEN Hui ,
  • SHEN Lisong ,
  • YANG Junyao
Expand
  • 1.Department of Laboratory Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    2.Faculty of Medical Laboratory Technology, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    3.Institute of Artificial Intelligence Medicine, Shanghai Academy of Experimental Medicine, Shanghai 200092, China
    4.Department of Laboratory Medicine, Shenzhen Second People′s Hospital, Guangdong Province, Shenzhen 518035, China
    5.Clinical Research Unit, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
SHEN Lisong, E-mail: lisongshen@hotmail.com
YANG Junyao, E-mail: yangjunyao@xinhuamed.com.cn.

Received date: 2025-05-29

  Accepted date: 2025-06-30

  Online published: 2025-12-03

Supported by

National Natural Science Foundation of China(81802082);Natural Science Foundation of Shanghai Science and Technology Innovation Action Plan(21ZR1441500);Medical Engineering Cross Fund of Shanghai Jiao Tong University(YG2025QNB48);Hospital Funded Clinical Research, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine(24XHCR04B)

Fold

Abstract

Objective ·To investigate the expression and tumor-promoting mechanism of the long non-coding RNA (lncRNA) LINC01123 in gastric cancer and evaluate its potential as a novel diagnostic biomarker and therapeutic target. Methods ·Differential expression analysis of lncRNAs between gastric cancer and normal tissues was performed based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets (GSE95667, GSE99416) by using R software. LINC01123 was identified as the candidate of interest. Its expression was validated in gastric cancer cell lines and clinical tissue samples by using qRT-PCR. The biological effects of LINC01123 on cell proliferation and metastasis were evaluated in vitro through gene overexpression and knockdown by utilizing CCK-8, colony formation, wound healing, and Transwell migration and invasion assays. In vivo, a subcutaneous xenograft tumor model in nude mice was established to assess the effect of LINC01123 on tumor growth. ATP and lactate production were measured to evaluate the role of LINC01123 in glycolysis. Transcriptome sequencing and Gene Set Enrichment Analysis (GSEA) were conducted to explore related pathways. RNA pull-down combined with mass spectrometry was used to identify proteins interacting with LINC01123. The binding region was predicted using the catRAPID database and validated by constructing α-enolase (ENO1) protein truncation mutants and performing RNA immunoprecipitation (RIP) assays. Functional interaction studies were carried out to determine whether ENO1 mediates the oncogenic effect of LINC01123. Results ·LINC01123 was upregulated in gastric cancer tissues and cell lines and was associated with poor patient prognosis (P=0.021). Functional assays demonstrated that LINC01123 promoted proliferation, migration, invasion, and glycolysis of gastric cancer cells such as MKN-45 in vitro, and enhanced tumor growth in vivo (all P<0.05). Mechanistically, LINC01123 was predominantly localized in the cytoplasm and bound to the 97‒237 amino acid region of ENO1 protein. Further studies showed that ENO1 knockdown in LINC01123-overexpressing cells partially reversed the proliferative and migratory effects of LINC01123 (all P<0.05) , indicating that ENO1 upregulation enhances the tumor-promoting function of LINC01123. Conclusion ·LINC01123 is highly expressed in gastric cancer and promotes tumor progression by binding to ENO1 protein and enhancing proliferation, migration, invasion, and glycolysis. LINC01123 holds promise as a novel diagnostic and prognostic biomarker and a potential therapeutic target for gastric cancer.

Key words： LINC01123; gastric cancer; α-enolase; long non-coding RNA; proliferation

Cite this article

ZHANG Shuqiong , KE Xing , ZHAO Xinghe , CHEN Xiaocui , ZHENG Haodong , CHEN Hui , SHEN Lisong , YANG Junyao . LINC01123 promotes proliferation and glycolysis of gastric cancer via binding to ENO1[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(11) : 1443 -1457 . DOI: 10.3969/j.issn.1674-8115.2025.11.004

References

[1] ARNOLD M, PARK J Y, CAMARGO M C, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035[J]. Gut, 2020, 69(5): 823-829.
[2] KIM H, HWANG Y, SUNG H, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort[J]. Cancer Res Treat, 2018, 50(2): 582-589.
[3] SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1): 17-48.
[4] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[5] PICARD M. Why do we care more about disease than health?[J]. Phenomics, 2022, 2(3): 145-155.
[6] GUTSCHNER T, DIEDERICHS S. The hallmarks of cancer: a long non-coding RNA point of view[J]. RNA Biol, 2012, 9(6): 703-719.
[7] DE LOS SANTOS M C, DRAGOMIR M P, CALIN G A. The role of exosomal long non-coding RNAs in cancer drug resistance[J]. Cancer Drug Resist, 2019, 2(4): 1178-1192.
[8] ZHAO J, XU H, SU Y H, et al. Emerging regulatory mechanisms of N6-methyladenosine modification in cancer metastasis[J]. Phenomics, 2023, 3(1): 83-100.
[9] HUA Q, JIN M M, MI B M, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis[J]. J Hematol Oncol, 2019, 12(1): 91.
[10] SHANG T, ZHOU X, CHEN W. LINC01123 promotes the progression of colorectal cancer via miR-625-5p/LASP1 axis[J]. Cancer Biother Radiopharm, 2021, 36(9): 765-773.
[11] XIAO Z Q, LIU Y, ZHAO J J, et al. Long noncoding RNA LINC01123 promotes the proliferation and invasion of hepatocellular carcinoma cells by modulating the miR-34a-5p/TUFT1 axis[J]. Int J Biol Sci, 2020, 16(13): 2296-2305.
[12] YANG Y, ZHENG Y, ZHANG H L, et al. An immune-related gene panel for preoperative lymph node status evaluation in advanced gastric cancer[J]. Biomed Res Int, 2020, 2020: 8450656.
[13] YE S C, SUN B L, WU W Y, et al. LINC01123 facilitates proliferation, invasion and chemoresistance of colon cancer cells[J]. Biosci Rep, 2020, 40(8): BSR20194062.
[14] ZHANG M, HAN Y G, ZHENG Y, et al. ZEB1-activated LINC01123 accelerates the malignancy in lung adenocarcinoma through NOTCH signaling pathway[J]. Cell Death Dis, 2020, 11(11): 981.
[15] ZHANG P R, LONG Q M, ZENG S Y, et al. FOXC1-induced LINC01123 acts as a mediator in triple negative breast cancer[J]. Cancer Cell Int, 2020, 20: 199.
[16] SUGAHARA T, NAKAJIMA H, SHIRAHATA S, et al. Purification and characterization of immunoglobulin production stimulating factor-II beta derived from Namalwa cells[J]. Cytotechnology, 1992, 10(2): 137-146.
[17] HUANG H, TANG S, JI M, et al. p300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis[J]. Mol Cell, 2018, 70(4): 663-678.e6.
[18] LóPEZ-ALEMANY R, LONGSTAFF C, HAWLEY S, et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against α-enolase[J]. Am J Hematol, 2003, 72(4): 234-242.
[19] HUA Q, WANG D L, ZHAO L, et al. AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC[J]. Cancer Cell Int, 2021, 21(1): 525.
[20] YU S M, LI N, HUANG Z B, et al. A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1[J]. Cell Death Dis, 2018, 9(12): 1184.
[21] BARLEBO AHLBORN L, ?STRUP O. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA[J]. APMIS, 2019, 127(5): 329-336.
[22] TRUJANO-CAMACHO S, CANTú-DE LEóN D, PéREZ-YEPEZ E, et al. HOTAIR promotes the hyperactivation of PI3K/Akt and Wnt/β-catenin signaling pathways via PTEN hypermethylation in cervical cancer[J]. Cells, 2024, 13(17): 1484.
[23] HU Y R, YU Y C, YOU S W, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer[J]. Mol Cancer, 2017, 16(1): 174.
[24] LI H, MA X H, YANG D S, et al. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2[J]. J Cell Biochem, 2020, 121(2): 1353-1361.
[25] GUO Y M, YUE P R, WANG Y M, et al. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis[J]. Biomed Pharmacother, 2019, 118: 109255.
[26] RAY R, MILLER D M. Cloning and characterization of a human c-myc promoter-binding protein[J]. Mol Cell Biol, 1991, 11(4): 2154-2161.
Options
Outlines

/

〈 〉